Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Ventyx Biosciences, Inc. (Nasdaq: VTYX) announced the successful closing of its upsized initial public offering, raising approximately $174.3 million by offering 10,893,554 shares at $16.00 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ventyx Biosciences, Inc. (Nasdaq: VTYX) announced the successful closing of its upsized initial public offering, raising approximately $174.3 million by offering 10,893,554 shares at $16.00 per share. This includes the full exercise of the underwriters' option for 1,420,898 additional shares. The shares began trading on Nasdaq on October 21, 2021. The company focuses on developing therapies for inflammatory diseases and autoimmune disorders, with a clinical pipeline that includes drug candidates targeting various conditions.
Positive
- Successfully raised approximately $174.3 million from the IPO.
- Full exercise of the underwriters' option indicates strong market interest.
Negative
- None.
Details
News Market Reaction – VTYX
The recorded move for VTYX in the trading session of this news was -9.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ENCINITAS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today the closing of its upsized initial public offering of 10,893,554 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,420,898 additional shares, at an initial public offering price of
Jefferies, Evercore ISI and Piper Sandler acted as joint book-running managers for the offering. LifeSci Capital also acted as an underwriter for the offering.
Registration statements relating to the offering have been filed with the Securities and Exchange Commission and became effective on October 20, 2021. Copies of the registration statements related to the offering are available at www.sec.gov. The offering was made only by means of a prospectus, forming a part of the effective registration statements. Copies of the final prospectus may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; and Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Ventyx
Ventyx is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. Ventyx is headquartered in Encinitas, California.
Contacts
For more information, please contact:
Investor Relations Contact:
Patti Bank
Managing Director
Westwicke Partners
(415) 513-1284
IR@ventyxbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.